Business Context and Reporting Period
This Form 8-K was filed by Galecto, Inc. on October 31, 2022, under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Exhibits). The filing concerns topline results from the Phase 1b/2a GULLIVER-2 clinical trial, which the company stated would be presented at the American Association for the Study of Liver Diseases’ The Liver Meeting 2022, held November 4–8, 2022.
The request identifies the company as Damora Therapeutics, Inc.; however, the filing text identifies the registrant as Galecto, Inc. and lists common stock trading under the symbol GLTO on The Nasdaq Global Select Market.
Financial and Operating Metrics
This filing does not provide revenue, net income, cash flow, margins, debt, liquidity, cash balance, or other financial performance metrics. It is a Regulation FD disclosure focused on clinical-trial results.
Material Changes Versus the Prior Comparable Period
The filing does not provide comparative-period financial information or quantify changes from a prior period.
Guidance, Outlook, Risks, and Unusual Items
- The company announced that certain topline GULLIVER-2 results would be presented at an upcoming medical conference.
- The filing itself does not include the underlying topline results, detailed efficacy or safety data, development guidance, or regulatory milestones.
- The press release referenced as Exhibit 99.1 is not included in the provided filing text, so the nature and significance of the trial results cannot be evaluated from this document alone.
- The disclosed information, including Exhibit 99.1, was furnished under Regulation FD and was not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference, except where expressly stated.
Key Facts for Investors to Verify
- Confirm the registrant identity, because the supplied request names Damora Therapeutics, Inc., while the filing names Galecto, Inc.
- Review Exhibit 99.1 for the actual GULLIVER-2 topline efficacy, safety, enrollment, endpoint, and statistical results.
- Assess whether the announced clinical findings support continued development, additional trials, or regulatory engagement.
- Consult the company’s periodic reports for cash resources, operating expenses, financing needs, debt, and liquidity runway, none of which are disclosed in this Form 8-K.